3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
12
Neoplasms
10
Multiple Myeloma
8
Prostatic Neoplasms
6
Neoplasm Metastasis
5
Giant Cell Tumor of Bone
5
Fractures, Bone
4
Recurrence
3
Osteoporosis
3
Bone Neoplasms
3
Bone Diseases, Metabolic
3
Spinal Cord Compression
2
Smoldering Multiple Myeloma
2
Parathyroid Neoplasms
2
Lymphoma
2
Kidney Neoplasms
2
Giant Cell Tumors
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Thyroid Neoplasms
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplastic Processes
1
Neoplasms, Plasma Cell
1
Multiple Endocrine Neoplasia Type 1
1
Melanoma
1
Mastocytosis, Systemic
1
Lymphoma, Non-Hodgkin
1
Interventions
Cyclophosphamide
20
Trastuzumab
12
Epirubicin
12
Doxorubicin
12
Docetaxel
11
Paclitaxel
10
Filgrastim
8
Carboplatin
7
Radiotherapy
6
Bevacizumab
5
Neoadjuvant Therapy
4
Lapatinib
4
Granulocyte Colony-Stimulating Factor
4
Albumin-Bound Paclitaxel
4
tipifarnib
3
pertuzumab
3
pegfilgrastim
3
Thiotepa
3
Taxes
3
Tamoxifen
3
Surgical Procedures, Operative
3
Melphalan
3
Fluorouracil
3
Chemotherapy, Adjuvant
3
Capecitabine
3
130-nm albumin-bound paclitaxel
3
Peripheral Blood Stem Cell Transplantation
2
Magnetic Resonance Spectroscopy
2
Immunohistochemistry
2
Flow Cytometry
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Inflammatory Breast Neoplasms
×
Denosumab
×
Clear all
NCT02682693
2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2
Completed
780 enrolled